Literature DB >> 33314312

Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.

Elizabeth M Kline1,2, Madelyn C Houser1,3, Mary K Herrick1,4, Philip Seibler5, Christine Klein5, Andrew West6, Malú G Tansey4.   

Abstract

Idiopathic Parkinson's disease (iPD) is a movement disorder characterized by the degeneration of dopaminergic neurons and aggregation of the protein α-synuclein. Patients with iPD vary in age of symptom onset, rate of progression, severity of motor and non-motor symptoms, and extent of central and peripheral inflammation. Genetic and environmental factors are believed to act synergistically in iPD pathogenesis. We propose that environmental factors (pesticides and infections) increase the risk for iPD via the immune system and that the role of PD risk genes in immune cells is worthy of investigation. This review highlights the major PD-relevant genes expressed in immune cells and key environmental factors that activate immune cells and, alone or in combination with other factors, may contribute to iPD pathogenesis. By reviewing these interactions, we seek to enable the future development of immunomodulatory approaches to prevent or delay onset of iPD.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  immune; LRRK2; gene by environment; MHCII; inflammation

Mesh:

Substances:

Year:  2020        PMID: 33314312      PMCID: PMC8285924          DOI: 10.1002/mds.28411

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  123 in total

1.  Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration.

Authors:  Haeman Jang; David Boltz; Katharine Sturm-Ramirez; Kennie R Shepherd; Yun Jiao; Robert Webster; Richard J Smeyne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

2.  Association between Parkinson's disease and the HLA-DRB1 locus.

Authors:  Ismaïl Ahmed; Ryad Tamouza; Marc Delord; Rajagopal Krishnamoorthy; Christophe Tzourio; Claire Mulot; Magali Nacfer; Jean-Charles Lambert; Philippe Beaune; Pierre Laurent-Puig; Marie-Anne Loriot; Dominique Charron; Alexis Elbaz
Journal:  Mov Disord       Date:  2012-07-13       Impact factor: 10.338

3.  The function of α-synuclein.

Authors:  Jacob T Bendor; Todd P Logan; Robert H Edwards
Journal:  Neuron       Date:  2013-09-18       Impact factor: 17.173

4.  Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease.

Authors:  Wei Zhang; Kester Phillips; Albert R Wielgus; Jie Liu; Alberto Albertini; Fabio A Zucca; Rudolph Faust; Steven Y Qian; David S Miller; Colin F Chignell; Belinda Wilson; Vernice Jackson-Lewis; Serge Przedborski; Danielle Joset; John Loike; Jau-Shyong Hong; David Sulzer; Luigi Zecca
Journal:  Neurotox Res       Date:  2009-12-03       Impact factor: 3.911

5.  Pyrethroid insecticides evoke neurotransmitter release from rabbit striatal slices.

Authors:  J T Eells; M L Dubocovich
Journal:  J Pharmacol Exp Ther       Date:  1988-08       Impact factor: 4.030

6.  Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Lilia Marinova-Mutafchieva; Mona Sadeghian; Lauren Broom; John B Davis; Andrew D Medhurst; David T Dexter
Journal:  J Neurochem       Date:  2009-06-22       Impact factor: 5.372

Review 7.  Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?

Authors:  Philippa Marrack; John W Kappler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

8.  LRRK2 levels in immune cells are increased in Parkinson's disease.

Authors:  D A Cook; G T Kannarkat; A F Cintron; Laura M Butkovich; Kyle B Fraser; J Chang; N Grigoryan; S A Factor; Andrew B West; J M Boss; M G Tansey
Journal:  NPJ Parkinsons Dis       Date:  2017-03-28

9.  LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.

Authors:  Gregor Bieri; Michel Brahic; Luc Bousset; Julien Couthouis; Nicholas J Kramer; Rosanna Ma; Lisa Nakayama; Marie Monbureau; Erwin Defensor; Birgitt Schüle; Mehrdad Shamloo; Ronald Melki; Aaron D Gitler
Journal:  Acta Neuropathol       Date:  2019-03-29       Impact factor: 17.088

10.  A current review of cypermethrin-induced neurotoxicity and nigrostriatal dopaminergic neurodegeneration.

Authors:  Anand Kumar Singh; Manindra Nath Tiwari; Om Prakash; Mahendra Pratap Singh
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

View more
  19 in total

Review 1.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

Review 2.  GBA1 and The Immune System: A Potential Role in Parkinson's Disease?

Authors:  Zaid A M Al-Azzawi; Saman Arfaie; Ziv Gan-Or
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  2021 Workshop: Neurodegenerative Diseases in the Gut-Brain Axis-Parkinson's Disease.

Authors:  Gary M Mawe; Kirsteen N Browning; Fredric P Manfredsson; Michael Camilleri; Frank A Hamilton; Jonathan A Hollander; Beth-Anne Sieber; Patricia Greenwel; Terez Shea-Donohue; John W Wiley
Journal:  Gastroenterology       Date:  2022-02-08       Impact factor: 33.883

4.  Long noncoding RNA BACE1-antisense transcript plays a critical role in Parkinson's disease via microRNA-214-3p/Cell death-inducing p53-target protein 1 axis.

Authors:  Lina Li; Hongjuan Wang; Huicang Li; Xin Lu; Yanxiang Gao; Xiaofeng Guo
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease.

Authors:  Zhu Liu; Qingli Fan; Shizheng Wu; Yaqi Wan; Yancheng Lei
Journal:  Lipids Health Dis       Date:  2021-04-19       Impact factor: 3.876

6.  Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease.

Authors:  Lucas Caldi Gomes; Ana Galhoz; Gaurav Jain; Anna-Elisa Roser; Fabian Maass; Eleonora Carboni; Elisabeth Barski; Christof Lenz; Katja Lohmann; Christine Klein; Mathias Bähr; André Fischer; Michael P Menden; Paul Lingor
Journal:  Clin Transl Med       Date:  2022-01

Review 7.  The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease.

Authors:  Zhijun Miao; Jinwei Bai; Li Shen; Rajeev K Singla
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

8.  Precision Medicine on the Fly: Using Drosophila to Decipher Gene-Environment Interactions in Parkinson's Disease.

Authors:  Souvarish Sarkar; Mel B Feany
Journal:  Toxicol Sci       Date:  2021-08-03       Impact factor: 4.109

Review 9.  Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.

Authors:  Johan Wallin; Per Svenningsson
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 10.  Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies.

Authors:  Ivette M Sandoval; David J Marmion; Kimberly T Meyers; Fredric P Manfredsson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.